Sanofi has agreed to buy Kadmon Holdings for $1.9 billion, the latest in a string of acquisitions the French pharmaceutical giant has used to add new drugs and technologies to its portfolio.
The deal, announced Wednesday, has Sanofi paying $9.50 per share in cash for Kadmon, a roughly 77% premium to the biotech’s Tuesday closing price and 113% more than its average trading price over the last two months. The acquisition gives Sanofi rights to Rezurock, a drug for graft-versus-host disease the Food and Drug Administration approved in July.
The buyout is the sixth largest, and features the third highest premium, in what’s been a comparatively slow year for biotech buyouts, according to data from Biopharma Dive. It’s also the sixth acquisition by Sanofi since the beginning of last year, a flurry of activity worth some $10 billion and the most of any pharmaceutical company over that span.
Those deals have given Sanofi a variety of different assets, from a messenger RNA vaccine platform to “off-the-shelf” cell therapies, and together represent a push by the drugmaker to remake itself after pivoting from the cardiovascular and diabetes research for which it’s long been known. READ MORE
By Ben Fidler
Source: biopharmadive.com
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”